Kailera Therapeutics Raises $600 Million
Kailera Therapeutics, an obesity drug startup, has secured $600 million in funding from investors, marking one of the largest private financing rounds for a biotech company this year.
The financing was led by Bain Capital's private equity group and included investments from Royalty Pharma and sovereign wealth funds in Canada and Qatar, as well as additional funding from Kailera's founding investors.
The deal highlights the ongoing interest in weight loss drugs, despite some clinical disappointments in recent years.
- The Series B round was announced nearly a year after Kailera's launch with $400 million in funding.
- The investment comes shortly after Pfizer announced plans to acquire Metsera, another privately held obesity drug developer, for $4.9 billion.
Author's summary: Kailera Therapeutics raises $600 million in funding.
More News
- Warminster man accused of killing girlfriend begins trial
- Are Twiggy Forrest’s green goals uneconomic or has China bounced him? - Switzer Daily
- Jaecoo expands SUV line-up with launch of compact J5 revealed
- Las Vegas traffic deaths hit 127 in 2025
- Call It What It Is: Genocide
- Trail Blazers' Deandre Ayton replacement is already turning heads
- BU registration changes to Friday, students respond
- Unknown issue causes areawide power outage for Juneau
- Madera High School's Memorial Stadium set to be completely renovated
- Younger Priests Remain More Conservative Than Older Priests in US, Survey Says